ONCOLOGY

Most initial discussions occur close to death.

3 of 10 pregnant patients who continued imatinib experienced adverse issues.

A technology appraisal committee was unclear on whether the treatment is superior to current chemotherapeutic regimens

Signature validated in patients from the CLL8 study.

Nearly 6-fold increase in risk for death.

95% achieved CCyR at 12 months of dasatinib 50 mg.

Almost one-third of patients achieved stringent complete response.

Strategies to better tailor effective treatments are needed.

Expert recommendations commission by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

More than 4 in 10 patients achieved complete remission.

Adjusted mortality risk was 88% higher for nonwhite patients.

We report a successful allogeneic transplantation and long-term engraftment of CRISPR–Cas9–edited stem cells in a patient with HIV and acute lymphoblastic leukemia.

More than 1 in 10 aged 15-19 years at diagnosis had very low BMD.

Bisphosphonates, denosumab are preferred.